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Validation of High Gradient Magnetic Field Based
Drug Delivery to Magnetizable Implants Under Flow
Zachary G. Forbes*, Member, IEEE, Benjamin B. Yellen, Derek S. Halverson, Gregory Fridman,
Kenneth A. Barbee, and Gary Friedman
Abstract—The drug-eluting stent’s increasingly frequent occur-
rence late stage thrombosis have created a need for new strategies
for intervention in coronary artery disease. This paper demon-
strates further development of our minimally invasive, targeted
drug delivery system that uses induced magnetism to administer
repeatable and patient specific dosages of therapeutic agents to spe-
cific sites in the human body. Our first aim is the use of magnetiz-
able stents for the prevention and treatment of coronary restenosis;
however, future applications include the targeting of tumors, vas-
cular defects, and other localized pathologies. Future doses can
be administered to the same site by intravenous injection. This
implant-based drug delivery system functions by placement of a
weakly magnetizable stent or implant at precise locations in the
cardiovascular system, followed by the delivery of magnetically
susceptible drug carriers. The stents are capable of applying high
local magnetic field gradients within the body, while only exposing
the body to a modest external field. The local gradients created
within the blood vessel create the forces needed to attract and hold
drug-containing magnetic nanoparticles at the implant site. Once
these particles are captured, they are capable of delivering ther-
apeutic agents such as antineoplastics, radioactivity, or biological
cells.
Index Terms—Magnetic drug delivery, magnetic separation car-
diovascular disease, stents.
I. INTRODUCTION
CANCER chemotherapeutic agents have been found to haveapplications in many realms of clinical medicine [1]–[3].
The best approach for localized pathology is to administer drugs
only at the site where needed. By delivering the drug locally,
the toxicity of the drug to the rest of the body can be reduced
while maintaining the desired therapeutic benefit at the site of
interest. Thus, the ability to deliver large concentrations of drugs
only at the site of interest is of major importance for both the
pharmaceutical industry and for clinicians.
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Biological polymers, liposomes, hydrogels, viruses, and
other controlled release carriers have been widely investigated
[4]–[6]. These vehicles release therapeutic agents under the
influence of ultrasound, pH, temperature, or chemical interac-
tion, but in many cases, however, the drug delivery vehicles
do not have a mechanism for localization where it is possible
to deliver high concentrations of drugs with minimally inva-
sive techniques. This is especially true when repeat dosing is
required. The magnetic drug delivery system proposed herein
overcomes many of these difficulties, and provides a method for
concentrating drugs at selected sites in the body with minimal
stress on the patient. This system makes use of the fact that
conventional stents, which are implanted in various part of the
body, can be modified with a thin layer of magnetic coating
or by increasing magnetic precipitates within the stent. Such
modifications will render the implant attractive to injected
magnetic nanoparticles. A primary example is a cardiovascular
stent commonly employed to prevent vessel constriction. In
this paper we focus on drug delivery in arterial vasculature, but
similar techniques may find applications for other diseases.
A. Stents and Restenosis
Stents are metallic or polymeric tubes made in a wide range
of physiologically appropriate diameters and lengths. Currently
the most commonly used materials for stents are 316L stain-
less steel or nickel–titanium (Nitinol) [7]. Stents have been rou-
tinely used over the last 15 years in percutaneous transluminal
coronary angioplasty (PTCA), a procedure for the treatment of
severe, symptomatic coronary stenosis [1]. In-stent restenosis
(the re-closing of the vessel) remains a major limitation in coro-
nary stenting. Restenosis is generally considered a local vas-
cular manifestation of the biological response to injury. The in-
jury as a result of catheter insertion and balloon inflation con-
sists of denudation of the endothelium and stretching of the me-
dial smooth muscle [1].
There are several treatment options in practice or under
investigation for treating restenosis. Local drug delivery can
limit systemic exposure, thereby reducing the risk of systemic
toxicity. Techniques for local drug delivery to arterial tissue
that have been described include application of drug via local
catheter injection, direct coating of the stent with drug, coating
of the stent with a drug-containing biodegradable polymer, and
hydrogel/drug coating [1]–[3]. Biodegradable stents have also
been described [8].
Problems with these technologies, include damage to the
polymer layer during implantation (causing portions to sever,
break off and cause clot formation), the inability to deliver
effective concentrations, one-time dosage limitations, and, in
0018-9294/$25.00 © 2008 IEEE
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the case of biodegradable stents, mechanical compromise. An
additional concern with the polymer-coated drug-eluting stents
is limitation of the endothelialization necessary to cover the
stent and prevent the bare metal from coming in long contact
with the blood, thereby leading to clot [8].
B. Proposed Design and Comparison to Previous Work
Magnetic targeting of therapeutic agents to specific sites in
the body enjoys certain advantages over other drug delivery
methods. One advantage is that magnetic colloids can be
injected into the bloodstream and guided to the targeted area
with external magnetic fields [9]–[13]. This technique, which
requires only a simple injection, is far less invasive than surgical
methods for targeted drug delivery. Magnetic particles com-
posed of magnetite are well tolerated by the human body [14].
Also, magnetic fields are well suited for biological applications
as they are not screened by biological fluids and do not interfere
with most biological processes [15]–[18]. Previous attempts
to use magnetic particles in these applications have relied on
high gradient magnetic fields produced by magnets external
to the body to direct magnetic particles to specific locations
[9]–[14]. This limits the range of their applications. The main
disadvantage of this approach is that externally generated mag-
netic fields apply relatively small and insufficient local forces
on micron and submicron sized particles.
Regardless of the size of the particles or implant, the basic
physics of magnetic particle capture is essentially the same. The
force on a magnetic particle can be expressed as
(1)
where is the magnetization of a particle of volume , sub-
jected to an applied magnetic field gradient, , produced by a
magnetic implant. As can be seen from the above equation, two
critical factors are responsible for the force on a superparam-
agnetic particle, namely: 1) the particle’s magnetization, which
for superparamagnetic materials is proportional to the applied
magnetic field; and 2) the magnetic field gradient at the position
of the particle [19], [20]
From basic physical principles, it can be shown that a single
source cannot simultaneously maximize both the particle mag-
netizing field and the field gradient in all space. Sources de-
signed to produce strong magnetic field gradients by definition
produce field that decays very quickly, and can only magnetize
the drug carriers in the immediate vicinity. On the other hand,
sources designed to produce far penetrating magnetic fields can
effectively magnetize the bulk of the carriers, but can only apply
weak forces on the particles because their magnetic field gra-
dient is weak (i.e., its magnetic field decays too slowly). Forces
produced by a single magnet decay very quickly because not
only does the gradient reduce rapidly with distance away from
the magnet, but also the magnetizing field decays quickly.
The novelty of our magnetic targeting system is that it inde-
pendently controls the magnetizing field and the magnetic field
gradient. This drastically reduces the rate at which the magnetic
force decays with distance and permits much greater forces to
be applied to injected drug carriers. A conceptual drawing of
the implant-based magnetic drug delivery system can be found
Fig. 1. Conceptual image of a magnetically patterned stent capture injected
magnetic particle drug carries under the application of an external magnetic
field.
in Fig. 1. The primary focus of our two-source method is an
implant-based drug delivery system, which operates by place-
ment of a magnetic implant (a stent or cylindrical endovascular
implant) at designated sites in the cardiovascular system and
then attracting to the designated sites injected doses of magnet-
ically susceptible drugs. This is accomplished with the aid of a
modest and uniform, external magnetic field. This “two source
system” allows for independent control over the magnetizing
field and the field by using two separate magnetic field sources.
One source is designed to produce far-reaching magnetic field in
order to increase the magnetization of all the injected carriers to
the point of magnetic saturation. Far-penetrating fields are most
typically generated with large electromagnets held external to
the body. The second magnetic field source is the magnetizable
stent providing a high local field gradient when saturated by the
external field.
Magnetic microspheres or nanospheres, which can be de-
signed to carry virtually any type of drug or medical agent, are
attracted to regions of the strongest magnetic field gradients.
Consequently, our research is focused on designing biocompat-
ible implants that produce strong magnetic field gradients near
the surface of the implant so that sufficient doses of drug can be
captured. One key advantage to this drug delivery system is that
the implant can be inserted by minimally invasive techniques
such as catheterization, as opposed to surgical techniques used
to implant other drug delivery devices. For example, in the
treatment of coronary atherosclerosis, the ability to deliver
growth-inhibiting drugs to the site of stent implantation can
greatly reduce restenosis.
The magnetic force on particles in the cardiovascular system
is in competition with drag forces induced by the high flow rate
of blood. However, theoretical models predict that the magnetic
force applied in our systems can overcome drag forces, leading
to significant particle capture. Results from theoretical simula-
tions have provided adequate flow models demonstrating the
functionality and effectiveness of magnetic drug delivery sys-
tems [21], [22].
C. Ex Vivo Flow Studies
Previous experiments in parallel plate flow chambers demon-
strated the ability to capture magnetic particles onto a magnet-
ically plated stainless steel mesh in physiologically significant
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Fig. 2. (a) 304 stainless steel rolled stent. The stent is 5 mm in diameter by 2
cm in length. The wire diameter is 150 m. (b) 302 stainless steel compression
spring. The spring is 3 mm in diameter by 2 cm in length. The wire diameter is
355 m.
flow rates. A parallel plate flow chamber was designed and ma-
chined to accommodate an unrolled stent, consisting of a section
of magnetizable stainless steel mesh mounted in a flow system
that could mimic the average coronary artery flow velocity of
15 cm/s. Having tested the basic concept, this work will focus
on the evaluation of in vitro, pipe flow experiments using rolled
mesh structures or stainless steel springs. These studies are in-
tended to motivate future in vivo experiments and evaluate the
potential for delivering controlled dosages of drug onto the im-
plant by examining the ability to capture submicron scale mag-
netic particles under simulated arterial blood flow conditions.
II. MATERIALS AND METHODS
A. Stent Material Selection and Electrodeposition
Two different grades of stainless steel were selected as
stent-simulating models. The first material selected consisted
of molded 304 grade stainless steel (150- m wire diameter,
450- m apertures). This material was found to have a larger
saturation magnetization than 316L steel, which is commonly
used in the manufacture of stents. Stent-like tubes of 304 stain-
less steel mesh were fabricated by heating the mesh, rolling it
into a cylinder (5-mm external diameter and 2-cm length), and
joining the overlapping edges using silver solder [Fig. 2(a)].
Although the rolled mesh material comprises a material which
is similar in principle to actual stents, the tubes are quite rigid
in comparison to commercially manufactured stents.
The second material used to simulate medical device implants
was composed of 302 stainless steel compression springs [2-cm-
long spring, 3-mm diameter, 355- m wire diameter; Fig. 2(b)].
These springs are more stent-like in geometry and mechanical
properties, but their wire diameter is 3–5 times thicker than
struts in a typical stent. These springs are highly magnetic, and
probably provide an optimistic estimate for examining different
alloys and their inherent abilities to capture particles under the
application of external magnetic fields.
Meshes and springs used here as stent models were electro-
plated with soft magnetic material [23]. Before each electro-
plating session, a fresh bath was prepared. 100 mL of elec-
troplating solution was prepared consisting of 0.45 M NiCl2,
0.65 M CoCL2, 30 g/dm-3 H3BO3 and a trace of Saccharin
(Sigma, MO) [24]. The bath solution was placed in a 1L glass
beaker, heated to 55 C at a pH of 3–3.5, and agitated by an
TABLE I
MASS-NORMALIZED SATURATION MAGNETIZATION DATA FOR THE
THREE SELECTED MODEL IMPLANT MATERIALS, IN BOTH PLATED
AND UNPLATED FORMS
air bubbler fixed at the bottom of the beaker. A Princeton Ap-
plied Research 363 Galvanostat/Potentiostat (Princeton Mea-
surements, NJ) was used as the current controller for electro-
plating. An industrial-grade sheet of cobalt (EMI, CA) 2 2
inches in size was connected as the counter-electrode, and the
test material was connected to the working electrode.
Plating height was determined by measuring the mass of the
sample before and after plating, using a digital balance with a
resolution of 10-5 grams. Attempts were made to ensure uni-
form plating by using an air-bubbler kept close to the sample,
and periodic rotation of the sample. Based on the sample geom-
etry and density of Cobalt Nickel alloy (assumed to be that of
pure Cobalt), the deposited thickness was calculated from the
difference in mass after electrodeposition. Two thicknesses of
Co/Ni, either 3.1 or 5.2 m, were deposited onto these rolled
mesh materials, with a 0 m height (unplated) representing the
control. Similarly, two separate thicknesses of Co/Ni alloy, ei-
ther 2.5 or 5.5 m, were deposited onto the springs, also with a
0 m height (unplated) representing the control.
B. Magnetic Property Measurements
Mgnetic properties of model implants were measured using a
Princeton Measurements MicroMag Alternating Gradient Mag-
netometer (AGM) (Princeton Measurements, NJ), a highly sen-
sitive instrument for detecting changes in the magnetic proper-
ties of materials (Flanders, 1988). The mesh was cut into 5-mm
circles using an industrial hole punch. Based on magnetic mo-
ment measurements, an effective saturation magnetization of the
sample was inferred by normalizing the magnetic saturation to
the mass of each sample. Since we were not concerned with
inherent material properties, shape effects of the sample wires
were not accounted for in saturation magnetization calculations.
Five samples of each material were measured by AGM, and the
normalized results averaged to obtain Ms per gram (Table I).
C. Magnetic Particle Selection
Commercially available superparamagnetic polystyrene
beads (Spherotech, IL) were used in all flow experiments.
These beads, composed of 20% -Fe2O3 magnetite by weight
and labeled with nile red fluorescent pigment, had a nominal
diameter of 350 nm with approximately 10% variance in size.
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Fig. 3. (left) Broad view of the pipe flow experimental setup, consisting of
PVC tubing with an enclosed stent or spring, mounted within a uniform field,
and connected to a flow pump. (right) Close up of magnetic mesh in the pipe
flow system between two magnetic coils.
Particles come in 2 mL water solutions concentrated at 1% w/v
or 2.274 109 particles/mL. Specifications from the manufac-
turer indicate that the magnetic material susceptibility of the
particles is on the order of –2.
D. Flow Experiments
The pipe flow experimental setup consisted of a 50-mL beaker
that supplied the flow pump with solution via a 20-mm-long
polyvinyl chloride (PVC) tube (Fig. 3). The pump passes the
particle dose through a 60 mm long PVC tube, into which the
rolled mesh or spring was gently inserted. The spring is mounted
between two solenoid coils with iron cores. Current of 1–5
amperes was passed through the coils with a bipolar operational
power supply/amplifier (Kepco, NY) to generate the external
magnetic field. In each case, a Lakeshore Model 410 Gaussmeter
and Probe (Lakeshore Cryotronics, OH) was used to verify the
applied field (most often 500 Gauss). The output of the tubing
was captured into a 50-mL centrifuge tube for capture analysis.
A variable flow peristaltic pump (Fisher, IL), which produced
pulsatile flow, was used for these flow experiments.
For the molded 304 grade steel stent flow experiments, three
repetitions were performed for each plating thickness: 0 (un-
plated), 3.1, and 5.2 m of Co/Ni. It should be noted that un-
plated 304 steel still maintains inherent paramagnetic proper-
ties, increased by plated layers. For all flow experiments using
the 5-mm molded stents, a PVC tube with 5mm inner diam-
eter was selected to be consistent with the outer dimensions
of the rolled stent. A 25-mL solution of magnetic particles in
deionized water at 1% by volume particle concentration was se-
lected as the first dose size. The sample was vortexed for 10 s
immediately before delivery to ensure uniform suspension. Be-
fore experiments began, the magnetic field was turned on, and a
25-mL priming dose of DI water was passed through the system.
The particle concentration was then introduced, followed by a
25-mL rinse with DI water in the continued presence of the
applied magnetic field. The 50-mL sample of flow experiment
output and rinse water was kept in a 50-mL centrifuge tube and
stored at 4 C for analysis.
For the compression spring flow experiments, again three rep-
etitions were performed for each plating thickness: 0 (unplated),
2.5, and 5.5 m of Co/Ni. For all flow experiments using the
3-mm springs, an approximately 3 mm in diameter polyethylene
tube was selected to fit the outer dimensions of the spring. A
10-mL solution of magnetic particles in deionized water at 1.0%
Fig. 4. (left) Surgical image of a placed stent within the common iliac of a
Sprague Dawley Rat. (right) After stent implantation and placement of an in-
jection catheter, radiolabeled magnetic particles are injected under exposure to
a 0.05T magnetic field.
by volume particle concentration was vortexed for 10 s immedi-
ately before delivery. Before experiments began, the magnetic
field was turned on, and a 10-mL priming dose of DI water was
passed through the system. The particle concentration was then
introduced, followed by a 10-mL rinse with DI water in the
continued presence of the applied magnetic field. The 20-mL
sample of flow experiment output and rinse water was kept in a
50-mL centrifuge tube and stored at 4 C for analysis.
E. AGM Analysis of Capture Efficiency
Flow output for each experiment was collected in a centrifuge
tube and refrigerated. Before each experiment had been per-
formed, a control sample of the input dose was prepared to com-
pare to flow output results. Each tube of flow output was vor-
texed for 10 s to resuspend the particles, and a 5- L sample was
added to a 5-mm-diameter glass cover slip. The slips were al-
lowed to dry for one hour and then analyzed in the AGM [25].
Five samples of each flow experiment were measured and then
compared to the magnetic measurement for the input sample for
each experimental concentration. The AGM has a 2.0% error.
F. Preliminary in Vivo Work
Under approved IACUC protocol 03446, rat angioplasty
was performed on 400g large adult Sprague Dawley rats. 302
grade stainless steel compressions springs (1-mm diameter by
5-mm length) were inserted into the iliac artery. Spherotech
magnetic particles, as described above, were labeled with Tech-
netium-99m for quantification of capture as well as gamma
imaging. Rats were exposed to a 0.05T uniform magnetic field
for 5 min while injected with the radiolabeled dose of magnetic
particles concentrated in 1 mL of normal saline. Instant thin
layer chromatography was used to evaluate the efficiency of
the radiolabeling technique, in addition to the preparation of
an equal standard dose for every study. This allows individual
experiment determination of radioactivity per particle injected
for accurate quantification of capture and biodistribution data.
In Fig. 4, surgical placement of the stent, as well as the magnetic
injection setup, are seen.
III. RESULTS
A. Molded Stent Flow Results
A fluorescent image of a 304 stent with captured 350-nm-di-
ameter superparamagnetic particles can be seen in Fig. 5. These
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Fig. 5. 5x (left) and 10x (right) images of densely captured 350nm particles on
a 304 Stainless Steel mesh. (left) Flow is in the upward direction of the image.
(right) Flow is applied towards the right of the image.
TABLE II
CAPTURE RESULTS FOR 5-mm DIAMETER 304 GRADE STEEL MOLDED
STENT FLOW EXPERIMENTS WITH 25-mL DOSES AT 1.0% BY VOLUME
CONCENTRATION OF 350 nm MAGNETIC PARTICLES. RESULTS ARE GIVEN
IN PERCENTAGE OF CAPTURE OF THE TOTAL PARTICLE DOSE, AND THE
APPROXIMATE NUMBER OF CAPTURED PARTICLES. ALTERNATING GRADIENT
MAGNETOMETER ERROR IS 2.0%
flow experiments were only performed for a particle concentra-
tion of 1.0% by volume, but demonstrated that for a large diam-
eter implant, at physiologically significant flow velocity for the
vessel diameter (based on average coronary output), magnetic
nanoparticles can be captured. Table II provides the percentage
of capture for unplated, as well as CoNi plating heights of 3.1
and 5.2 m. Results are given in percentage of capture of the
total particle dose, and the approximate number of captured par-
ticles.
B. Compression Spring Flow Experiments
These flow experiments were performed for particle concen-
trations of 1.0% by volume. For an average coronary artery
scaled implant at physiologically relevant flow velocity, mag-
netic nanoparticles can be captured. Table III provides the per-
centage of capture for unplated, as well as CoNi plating heights
of 2.5 and 5.5 m. Results are given in percentage of capture of
the total particle dose, and the approximate number of captured
particles.
Fig. 6 shows characteristic fluorescent images for each
plating height for experiments performed at a 1.0% by volume
concentration of 350-nm magnetic particles. Images can be
seen of the outside and inside of the spring. Due to the density
of capture, by inspection, it is difficult to differentiate between
the three samples.
C. Selected in Vivo Results
Rat studies have been completed at increasingly scaled down
dose sizes due to the success of targeting. The most desirable
TABLE III
THIS TABLE PRESENTS EXPERIMENTAL RESULTS FOR 302 STAINLESS STEEL
COMPRESSION SPRINGS THAT ARE UNPLATED, AND AT CO-NI PLATING
HEIGHTS OF 2.5 AND 5.5m, FOR A DOSE CONCENTRATION OF 1.0% 350 nm
MAGNETIC PARTICLES BY VOLUME IN DEIONIZED WATER. RESULTS ARE
GIVEN IN PERCENTAGE OF CAPTURE OF THE TOTAL PARTICLE DOSE,
AND THE APPROXIMATE NUMBER OF CAPTURED PARTICLES.
ALTERNATING GRADIENT MAGNETOMETER ERROR IS 2:0%
Fig. 6. 5x objective fluorescent images of captured 350 nm rhodamin-stained
magnetic particles on 302 stainless steel springs from pipe flow experiments.
(top) Image: unplated spring. (bottom) Image: 5.5 m CoNi plated spring.
end is minimizing the amount of magnetic material necessary
to obtain maximum therapeutic results.
Fig. 7 shows a gamma camera image of a 395g rat which
received a 4 mg/kg dose of magnetic particles under 5 min
of exposure to a 0.05 Tesla uniform magnetic field. The red
arrow points to the implanted stent location, demonstrating
a “hot spot” from its captured magnetic material content.
Particles were labeled at greater than 90% efficiency with
Technetium-99m, verified by thin layer chromatography. Fig. 8
shows the biodistribution of magnetic particles within various
tissues of the rat. Organ harvesting and weight normalization
was combined with measurement of a dose standard to de-
termine the amount of radioactivity per delivered magnetic
particle.
IV. DISCUSSION
As predicted from previous studies [12], a stent model of 304
grade stainless steel is capable of magnetically capturing signif-
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Fig. 7. Gamma image of captured particles to an implanted magnetic spring,
noted by the arrow. The large mass to the lower left is the liver, removed and
placed aside for clarity.
Fig. 8. Biodistribution of uncaptured particles per gram of tissue. Early studies
found the liver to peak in the short term, but to drop to lower levels after long
exposure to the applied magnetic field, indicating a long circulation life for the
used magnetic particles.
icant numbers of 350 nm magnetic particles without the addi-
tion of a plated layer of soft magnetic alloy. Upon addition of a
3.1 m plating layer, the saturation magnetization of the device
is increased to four times that of an unplated sample, but roughly
only a doubling of capture occurs. Further plating to a 5.2 m
height shows just a little over 10% increase in capture. These re-
sults indicate that the capturing abilities of the applied magnetic
forces are beginning to level off at the 17 emu/g normalized sat-
uration magnetization for this particular material and geometry.
Our prior theoretical models predicted that particles flowing in
the center of the vessel are much more difficult to capture, and
the plateau phenomena seen in numerical capture most likely
relates to an inability to magnetically force these particles’ tra-
jectories rapidly enough to trap them on the surface of the stent,
even with significant magnetic features upon it.
It is not surprising that an unplated 302 grade stainless steel
compression spring, with its high saturation magnetization, is
able to capture significant amounts of magnetic nanoparticles.
Due to the inherently high saturation magnetization of these
springs, very little benefit in terms of capture was obtained by
the addition of the two different plating heights of soft magnetic
alloy. Even when considering potential error due to loss of par-
ticles to the tubing, or the limitations of the AGM measurement
procedure, the dose concentration of 1.0% provided extremely
dense capture. Based on the free length and wire diameter of
these springs, they contain a total surface area of 1.93 cm . Ide-
alizing and neglecting the points of contact with the vessel wall
and if each particle is modeled as a cube with a 350-nm side,
1.57 109 particles would be necessary to provide a uniform,
single particle layer coating. Capture by the unplated spring at
concentration was nearly four times that amount.
In our first in vivo studies, for a 300-nm or greater particle, it
is not surprising to find a large distribution within the liver. We
were pleased to find that the lung distribution was low, and that
the blood distribution remained high. This demonstrates that the
particles have a long circulation life. While the studies to this
point only focus on local injection, the circulation data points in-
creasingly to the legitimacy of intravenous injection as a means
for particle delivery to the implant. It should also be noted that
high activity in the liver is also reflective of the large blood con-
tent within the organ, and early results at particle sizes of 100nm
are showing particle excretion from the liver into the duodenum.
Future studies will optimize This will aid in demonstrating that
the particles do not pose a risk of thombosis in the liver or other
tissues.
V. CONCLUSION
In summary, for a range of stent-like structures 3 to 5 mm
in diameter, with different geometries, and for normalized satu-
ration magnetizations from 3 to 150 emu/g, magnetic particles
were successfully captured at significant numbers. While a ma-
terial with such a high saturation magnetization as 302 grade
stainless steel may never be used for an endovascular implant,
it provided an opportunity to test the upper bounds of the full
latitude of the capture method, in vitro and in vivo. Strongly
paramagnetic or ferromagnetic stents would be impractical due
to the inability to safely perform MRI procedures on the pa-
tient in the future. Such materials would be at risk of torquing
within these large fields. As this technology claims preventive
and long term advantages, it is crucial to find a functional middle
ground between magnetic targeting capabilities and the safe use
of MRI technology for other pathology. As a result, we continue
to evaluate the deposition of soft magnetic alloy micro-features
onto otherwise nonmagnetic 316L (the current standard metal
for coronary stents) in order to meet both of these needs. Addi-
tionally, we are working with magnetic coatings that also allow
for proper expansion and mechanical behavior required for the
stent’s primary functionality. These may be chemically passi-
vated to further limit metallic ion leaching already commonly
seen with the use of bare metal stents. The results presented
here further validate the hypothesis that the method could be
successful by adjusting the amount of magnetic precipitates dis-
persed within a stent itself, or by the addition of small, soft mag-
netic features.
While we continue to evaluate dose ranges, magnetic field
exposure time, and administration route in rats, we have begun
the design of 316L grade stainless steel stents with electro-
plated magnetic features for larger animal models. We propose
the extension of our flow experiments to in vivo testing in
New Zealand White Rabbit (Drexel IACUC #16182 Study
of Magnetic Nano-sphere Delivery to a Magnetizable Stent).,
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in which human scale magnetic stents can be implanted in
order to complete the milestones proposed. These stents have
been designed at Drexel University and are in early stages of
preparation by a suitable third party. In vivo results balanced
with clinical perspective and engineering design will provide
the appropriate input to selection of the optimal grade of steel
or magnetic coating material and particle composition. It is the
intent to rationally develop an understanding of all parameters
and risk so that the technology can be easily adapted to existing
implant designs for any of the above mentioned applications,
with cardiac stents as the desired entry point.
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